Post-COVID-19 Condition Symptoms Among Emergency Department Patients Tested for SARS-CoV-2 Infection DOI Creative Commons
Patrick Archambault, Rhonda J. Rosychuk, Martyne Audet

и другие.

Research Square (Research Square), Год журнала: 2023, Номер unknown

Опубликована: Дек. 22, 2023

Abstract Importance: Symptoms of Post-COVID-19 Condition (PCC) are non-specific and can occur due to other medical conditions, making it a challenge distinguish PCC from health conditions. Objective: To compare the proportion emergency department (ED) patients who developed symptoms consistent with between those tested positive for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection time-matched negative. Design: Observational cohort study that enrolled consecutive eligible October 18, 2020, February 28, 2022. Setting: Thirty-three Canadian COVID-19 ED Rapid Response Network sites. Participants: Eligible were aged ≥18 years SARS-CoV-2. We excluded not contacted after 5 attempts, unable communicate language or cognitive barriers, deceased, reported subsequent test symptomatic infection. Exposure: SARS-CoV-2 Main outcome Measure:Based on World Health Organization (WHO) clinical case definition, our primary was reporting at least one new PCC-consistent symptom arising in three months visit still present three-month mark lasted >2 months. Results: Of 29,838 individuals assessed eligibility, 6,723 included (58% positive; 51% female; mean age, 54.4 [SD: 17.9]). Among 3,933 test-positive patients, 38.9% (1532/3933, 95% CI: 37.4-40.4%) 3 compared 20.7% (578/2790, 19.2-22.2%) test-negative patients. Test-positive experiencing each individual twice as often The top most frequently by post-exertional malaise, dyspnea memory problems. important predictor during index (adjusted OR=4.42). Conclusions Relevance: Over one-third proven acute met criteria post-index visit, however five also highlighting lack specificity WHO definition. Testing phase suspected should continue until specific biomarkers become available diagnosis treatment referral. Trial registration: Clinicaltrials.gov, no. NCT04702945

Язык: Английский

Post-COVID-19 condition symptoms among emergency department patients tested for SARS-CoV-2 infection DOI Creative Commons
Patrick Archambault, Rhonda J. Rosychuk, Martyne Audet

и другие.

Nature Communications, Год журнала: 2024, Номер 15(1)

Опубликована: Сен. 30, 2024

Язык: Английский

Процитировано

4
Discrimination of a single-item scale to measure intention to have a COVID-19 vaccine DOI Creative Commons
Julius Sim, Louise Smith, Richard Amlôt

и другие.

PLoS ONE, Год журнала: 2025, Номер 20(5), С. e0322503 - e0322503

Опубликована: Май 5, 2025

Aim When developing public health measures in a pandemic, it is important to examine attitudes and beliefs relating vaccination uptake. We report the discrimination of single-item intention scale derive cutpoints terms sensitivity (true positives) specificity negatives) relation subsequent status. Subject Methods In sample UK adults ( n =1119) recruited through an online survey platform, was measured on 0–10 numerical rating (0=very unlikely, 10=very likely) at beginning COVID-19 rollout (January 2021), self-reported status gathered after had been offered all (October 2021). Discrimination by area under receiver operating characteristic (ROC) curve. Results The responders reporting being vaccinated or unvaccinated were 1034 (92.4%) 85 (7.6%), respectively. ROC curve was.956 (95% CI.943,.967), indicating high degree discrimination. combined value greatest cutpoint 8 (sensitivity =.821, =.988). If, however, individual values are required be simultaneously optimized, this occurs point 6 =.886, =.871). Conclusion recommend as validated, practical measure practice, with optimal, unless when optimal cutpoint.

Язык: Английский

Процитировано

0
Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study DOI Creative Commons
Nicola Cherry, Anil Adisesh, Igor Burstyn

и другие.

Vaccine, Год журнала: 2024, Номер 42(5), С. 1168 - 1178

Опубликована: Янв. 25, 2024

Healthcare workers (HCWs) from an interprovincial Canadian cohort gave serial blood samples to identify factors associated with anti-receptor binding domain (anti-RBD) IgG response the SARS-CoV-2 virus. Members of HCW donated four months after their first immunization and again at 7, 10 13 months. Date type immunizations dates infection were collected each contacts, together information on immunologically-compromising conditions current therapies. Blood analyzed centrally for anti-RBD anti-nucleocapsid (Abbott Architect, Abbott Diagnostics). Records testing public health agencies used assess impact reporting errors estimates random-effects multivariable model fitted data. 2752 4567 vaccinated participants agreed donate least one sample. Modelling titer 8903 showed increase in vaccine dose infection. A decrease was found number since vaccination or infection, sharpest decline third dose. An regime that included mRNA1273 (Moderna) resulted higher IgG. Participants multiple sclerosis, rheumatoid arthritis taking selective immunosuppressants, tumor necrosis factor inhibitors, calcineurin inhibitors antineoplastic agents had lower Supplementary analyses those side-effects vaccination, no relation obesity titers women immunized early mid-pregnancy. Sensitivity analysis results suggested important bias self-report Creation a prospective central credibility presented here. Serial serology assessments, longitudinal analysis, provided effect enhanced accuracy clearer understanding medical other affecting vaccination.

Язык: Английский

Процитировано

2
Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan DOI Creative Commons
Takeshi Arashiro,

Yuzo Arima,

Jin Kuramochi

и другие.

Vaccine, Год журнала: 2023, Номер 41(47), С. 6969 - 6979

Опубликована: Окт. 13, 2023

Repeated emergence of variants with immune escape capacity and waning immunity from vaccination are major concerns for COVID-19. We examined whether the surge in Omicron subvariant BA.5 cases was due to or through vaccine effectiveness (VE) evaluation.A test-negative case-control study conducted 16 clinics/hospitals during BA.1/BA.2-dominant BA.5-dominant periods. VE against symptomatic infection estimated after adjusting age, sex, comorbidity, occupation, testing frequency, prior infection, close contact history, clinic/hospital, week, preventive measures. Absolute (aVE) calculated 2/3/4 doses, compared unvaccinated. Relative (rVE) calculated, comparing 3 vs 2 4 doses.13,025 individuals were tested periods similar baseline characteristics. For BA.1/BA.2, aVE 52 % (95 %CI:34-66) 14 days-3 months post-dose 2, 42 (29-52) > 6 71 (64-77) 3, 68 (52-79) 3-6 3. rVE 49 (38-57) 45 (18-63) BA.5, 56 (27-73) 32 (12-47) 70 (61-78) 59 (48-68) 50 (29-64) 74 (61-83) ≥ days 4. (45-65) 39 (27-48) 25 (-2-45) 30 (-6-54) 4.Booster doses initially provided high protection at a level that BA.1/BA.2. However, seemed shorter-lasting which likely contributed surge. Furthermore, low even among recent vaccinees. These results support introduction variant-containing vaccines emphasize need longer duration protection.

Язык: Английский

Процитировано

5
Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada DOI Creative Commons
Daniel K. Ting, Rhonda J. Rosychuk, Jeffrey P. Hau

и другие.

Vaccine, Год журнала: 2024, Номер 42(23), С. 126058 - 126058

Опубликована: Июнь 15, 2024

During the COVID-19 pandemic, clinical care shifted toward virtual and Emergency Department care. We explored feasibility of mRNA vaccine effectiveness (VE) estimation against SARS-CoV-2-related visits hospitalizations using prospectively collected data. estimated two-dose VE a test-negative design data from 10 participating sites Canadian Rapid Response Network (CCEDRRN). included patients presenting with symptoms nucleic acid amplification testing for SARS-CoV-2 between July 19 December 31, 2021. excluded unclear vaccination one or more than 2 doses by their visit. Among 3,405 eligible patients, adjusted was 93.3 % (95 CI 87.9–96.3 %) 7–55 days, sustained over 80 through 139 days post-vaccination. In stratified analyses, similar among select immune-compromising conditions, chronic kidney disease, lung unstable housing, reported illicit substance use. Two-dose visit high sustained, including vulnerable subgroups. Compared to administrative datasets, active enrolment enables standardization access indication supports separate assessment special population other settings, Departments consistently function during crises when alternate healthcare sectors become variably closed. Trial registration: Clinicaltrials.gov, NCT0470294.

Язык: Английский

Процитировано

1
Parent and family characteristics associated with reported pediatric influenza vaccination in a sample of Canadian digital vaccination platform users. An exploratory, cross-sectional study in the 2018-2019 influenza season DOI Creative Commons
Katherine Atkinson, Blaise Ntacyabukura, Steven Hawken

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)

Опубликована: Июль 22, 2024

Seasonal vaccination remains one of the best interventions to prevent morbidity and mortality from influenza in children. Understanding characteristics parents who vaccinate their children can inform communication strategies encourage immunization. Using a cross-sectional study, we described parental people reported vaccinating against during 2018/2019 cohort Canadian digital immunization record users. Data was collected free, Pan-Canadian tool, CANImmunize. Eligible accounts contained at least "child/dependent" record. Each characteristic (gender, age, family size, etc) tested for association with pediatric vaccination, multivariate logistic regression model fit. A total 6,801 CANImmunize met inclusion criteria. After collapsing dataset, final sample 11,381 unique dyads. Influenza 32.3% 42.0% parents. In analysis, receiving seasonal vaccine were most strongly associated reporting (OR 17.05, 95% CI 15.08, 19.28). Having larger size fewer transactions study period not vaccination. While there are several limitations this large-scale these results help future research area. Digital technologies may provide valuable source coverage data explore associations between individual behavior. Policy makers considering messaging want tailor efforts based on further improve uptake.

Язык: Английский

Процитировано

1
Characteristics and outcomes of patients with COVID-19 who return to the emergency department: a multicentre observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) DOI
Rhonda J. Rosychuk, Jaspreet Khangura,

Sylvia S Ortiz

и другие.

Emergency Medicine Journal, Год журнала: 2024, Номер 41(4), С. 210 - 217

Опубликована: Фев. 16, 2024

Unplanned return emergency department (ED) visits can reflect clinical deterioration or unmet need from the original visit. We determined characteristics and outcomes of patients with COVID-19 who to ED for COVID-19-related revisits.

Язык: Английский

Процитировано

0
Cervical Cancer Screening and Prevention Uptake in Females with Autism Spectrum Disorder DOI
Yachin Chen, James H. Powers, Christopher J. McDougle

и другие.

Journal of Autism and Developmental Disorders, Год журнала: 2024, Номер unknown

Опубликована: Сен. 18, 2024

Язык: Английский

Процитировано

0
Accuracy of the Canadian COVID-19 Mortality Score (CCMS) to predict in-hospital mortality among vaccinated and unvaccinated patients infected with Omicron: a cohort study DOI Creative Commons
Corinne M. Hohl,

David Seonguk Yeom,

Justin W. Yan

и другие.

BMJ Open, Год журнала: 2024, Номер 14(11), С. e083280 - e083280

Опубликована: Ноя. 1, 2024

Objective The objective is to externally validate and assess the opportunity update Canadian COVID-19 Mortality Score (CCMS) predict in-hospital mortality among consecutive non-palliative patients infected with Omicron subvariants at a time when vaccinations were widespread. Design This observational study validated CCMS in an external cohort variants dominant. We assessed potential rule improve its performance by recalibrating adding vaccination status subset of from provinces access data created adjusted (CCMS adj ). followed discharged for 30 days after their index emergency department visit or entire hospital stay if admitted. Setting External validation CCMS: 36 hospitals participating Emergency Department Rapid Response Network (CCEDRRN). Update : 14 CCEDRRN data. Participants Consecutive presenting departments. Main outcome measures In-hospital mortality. Results Of 39 682 eligible patients, 1654 (4.2%) died. included age, sex, residence type, arrival mode, chest pain, severe liver disease, respiratory rate level support predicted area under curve (AUC) 0.88 (95% CI 0.87 0.88) validation. Updating create changed weights homelessness, but only marginally improved performance, while did not. had AUC 0.91 0.89 0.92) scores <10 categorised as low risk <1.6%. A score>15 observed >56.8%. Conclusions remained highly accurate predicting through recalibration. Adding not performance. can be used inform patient prognosis, goals care conversations guide clinical decision-making COVID-19.

Язык: Английский

Процитировано

0
Vector induced humoral responses after rVSVΔG-ZEBOV-GP immunization identify vaccinated individuals and correlate with Ebola virus glycoprotein antibodies DOI
Prabha Chandrasekaran, Irina Maljkovic Berry, Viviane Callier

и другие.

The Journal of Infectious Diseases, Год журнала: 2024, Номер unknown

Опубликована: Дек. 24, 2024

Abstract Background While vaccine antigen-induced antibodies are often used as proxies for efficacy, immune responses to vectors less well-defined. We describe the kinetics of immunoglobulin (IgG) against vector (vesicular stomatitis Indiana virus [VSIV]) nucleoprotein (N) and inserted antigen (Ebola [EBOV]) glycoprotein (GP1,2) components rVSV-ZEBOV evaluate their use biomarkers confirm self-reported vaccination status. Methods selected 212 participants randomized (n = 107) or placebo 105). Levels IgG EBOV GP1,2 VSIV N were measured using an enzyme-linked immunosorbent assay a newly developed single-molecule array (Simoa) immunoassay, respectively. Results Anti-EBOV anti-VSIV first detected 10-14 days postvaccination, further increased at 28 days, remained stable through 360 days. Antibody titers significantly correlated (P &lt; 0.001) (r 0.47), 180 0.45), 0.59). At area under receiver operating characteristic curve (AUC) discriminated vaccinated from unvaccinated patients with high accuracy (AUC 0.965 IgG; AUC 0.945 anti-EBOV [P 0.001]). Conclusions report reliable measure vector-induced humoral after demonstrate assay's utility

Язык: Английский

Процитировано

0